News

Free Webinar Planned for Those Interested in Referring or Applying to NIH Undiagnosed Diseases Network


 

References

The Undiagnosed Diseases Network (UDN), a research project supported by the National Institutes of Health (NIH) Common Fund, brings together clinical and research experts from across the country to try to solve the most challenging medical mysteries. As part of this project, patients with longstanding unexplained symptoms can apply to receive an in-depth clinical and research examination at one of the UDN’s seven medical centers.

The National Organization for Rare Disorders (NORD) and the UDN will co-host a free webinar from 1 to 2 p.m. ET on Friday, June 3, for clinicians, researchers, and patients that will provide an overview of the UDN, discuss the application and evaluation process, and review financial considerations. Participants will also have the opportunity to hear from a patient who has been through the UDN clinical and research evaluation.

Speakers will include Katrina Dipple, MD, PhD, Departments of Human Genetics and Pediatrics, University of California, Los Angeles; Vandana Shashi, MD, Department of Pediatrics, Duke University Medical Center; Kimberly Splinter, MS, CGC, Genetic Counselor and Clinical Project Manager, UDN Coordinating Center, Harvard Medical School.

Register here for this free webinar. Questions may be directed to education@rarediseases.org.

Recommended Reading

Additional D1 biopsy increased diagnostic yield for celiac disease
MDedge Internal Medicine
NORD Announces 2016 Rare Impact Award Recipients
MDedge Internal Medicine
Free Summer Camp For Families of Children With Rare Diseases
MDedge Internal Medicine
NORD Speaks on Behalf of Continued Funding for NIH Undiagnosed Diseases Network
MDedge Internal Medicine
NIH and FDA Release a Draft Clinical Trial Protocol Template for Public Discussion
MDedge Internal Medicine
Large placebo effect seen in trial of maralixibat for primary biliary cholangitis
MDedge Internal Medicine
TSH antibody levels predict Graves relapse after thionamides
MDedge Internal Medicine
Tofacitinib an alternative treatment for refractory cutaneous dermatomyositis
MDedge Internal Medicine
FDA: Olanzapine can cause serious skin reaction
MDedge Internal Medicine
Study lays groundwork for refractory cutaneous lupus treatment algorithms
MDedge Internal Medicine